How Long Do Antidepressants Take to Work? A Realistic Timeline

The most common reason antidepressants fail is not that they do not work. It is that people stop taking them before they have had the chance to.

Reported discontinuation rates for antidepressants within the first three months range from 40 to 60 percent. Most of those people stopped during the window when side effects are most noticeable and mood improvement is least visible. Most of them stopped before their medication had a fair trial.

Understanding what antidepressants actually do week by week, and why the gap between first dose and felt benefit exists, changes how you manage this period. It changes whether you call your prescriber when you feel worse in week 2 or stop the medication. It changes whether you make it to week 8.

What This Page Covers

• Why antidepressants take weeks to produce mood benefit despite working quickly at the neurochemical level
• What typically changes in weeks 1, 2, 4, 6, and 8, and what to expect
• The specific symptoms that often improve first
• Why some patients are late responders who would be missed by early evaluation
• The dropout problem and what it costs
• How ongoing monitoring during this period changes outcomes

Why Antidepressants Do Not Work Immediately

Antidepressants, particularly SSRIs and SNRIs, begin their pharmacological action within hours. An SSRI blocks serotonin reuptake transporters from the first dose, increasing the availability of serotonin in the synaptic gap. That is not what takes time.

What takes time is the adaptive neurological response to that change.

Researchers estimate it takes 3 to 5 weeks for the brain to form new connections and improve how it processes emotional information after starting an antidepressant. Autoreceptors that regulate serotonin release must desensitize, allowing the increased serotonin availability to actually change how neurons communicate. Neuroplastic changes in regions like the hippocampus take time to develop.

The medication is not slow. Your brain’s adaptation to it is.

A Realistic Week-by-Week Timeline

Individual variation is significant, and the following is a pattern observed across many patients, not a guarantee for any single person.

Weeks 1 to 2: Adjustment without benefit

In the first 1 to 2 weeks, most patients experience the medication’s initial pharmacological effects without mood improvement. During the first few weeks, you are most likely to experience side effects as your body adjusts to the medication. Common experiences include:

• Nausea, particularly when taking the medication without food
• Mild headache or fatigue
• Disrupted sleep, either insomnia or increased sleepiness
• For SSRIs and SNRIs, sometimes a temporary increase in anxiety or restlessness in the first week

Mood benefit is typically absent in this phase. This is not evidence the medication is failing. This is the expected pharmacological sequence.

One third of patients also show some early positive signal by the end of week 1 or 2. A meta-analysis of 76 double-blind placebo-controlled trials found that one-third of total clinical benefit over six weeks can appear in the first week. But this early signal is not universal, and its absence does not predict failure.

Weeks 2 to 4: First signs of change

By weeks 3 to 4, the initial side effects typically begin to subside and the first signals of therapeutic benefit appear for many patients.

Importantly, physical symptoms often improve before emotional ones. Sleep may begin to normalize. Energy may increase. Appetite may stabilize. These are legitimate treatment signals, even if mood itself has not shifted.

In clinical studies, specific physical symptoms show significant improvement over the first four weeks, with the effect leveling off in the following weeks. Mood improvement is more gradual, due to the complex process involved with emotional processing.

Weeks 4 to 6: Meaningful mood improvement for most

For many patients, weeks 4 to 6 represent the first period of clear, sustained mood improvement. The American Psychiatric Association generally recommends 4 to 8 weeks for evaluation of full response. Studies show a clear separation from placebo by week 4, with many patients reaching 50 percent reduction in depressive symptoms within six weeks.

If you have had meaningful early improvement by weeks 2 to 4, this is a clinically useful signal: early responders are approximately 3.2 times more likely to achieve remission than those without early response, according to a naturalistic study of early response trajectories.

Weeks 6 to 12: Full effect and late responders

By weeks 6 to 8, most patients have reached a stable treatment response at their current dose. But a clinically important subgroup responds later.

More than half of subjects who eventually reached remission showed a pattern of delayed improvement, and their eventual outcome could not be predicted from early time points, according to the GENDEP study, a large randomized clinical trial analyzing individual trajectories of antidepressant response.

This is a critical finding. If your prescriber or you conclude the medication is not working at week 4 because you have not yet noticed improvement, you may be abandoning a treatment that would have produced remission by week 8 or 12. Early non-improvement does not rule out response or remission, particularly after 12 rather than 6 weeks. Routinely adapting pharmacological treatment because of limited early improvement would often be premature, according to a meta-analysis of 30 clinical trials.

Why People Stop Too Early

The sequence matters. Side effects come first. Mood benefit comes later. That gap creates a window of maximum dropout risk.

During weeks 1 to 3, a patient is most likely to experience nausea, disrupted sleep, and sometimes increased anxiety, without having seen a mood benefit yet. This is the period when the medication feels most like it is making things worse. It is also the period when the most patients stop.

The combination of delayed response onset and the emergence of side effects often disrupts medication adherence, and discontinuation rates in the first three months range from 40 to 60 percent.

Nobody checks in to see how you are doing in week 2. Nobody asks whether the nausea has improved or whether you are thinking of stopping. Most prescribers see patients monthly at best. By the time the next appointment arrives, many patients have already made their decision.

This is not a failure of willpower. It is a structural failure of how mental health care works. The medication’s critical first weeks go unmonitored.

What Happens If You Stop Too Early

The underlying condition goes untreated. Depression does not pause. The weeks when the medication needed more time are weeks during which symptoms persist.

Discontinuation syndrome can occur. SSRIs and SNRIs should not be stopped abruptly. Doing so can cause dizziness, flu-like symptoms, irritability, and in some cases, electric shock-like sensations in the head and extremities. Tapering is always the right approach.

The next trial starts lower. Patients who fail an initial SSRI are 12 to 38 percent less likely to respond to an alternative agent, according to clinical data. Those who fail to respond early may be more likely to become treatment resistant. Stopping early does not just delay recovery; it reduces the odds of the next treatment working.

About SiggyMD

The period between starting an antidepressant and knowing whether it is working is precisely when the absence of support does the most damage.

“I see it constantly,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “A patient starts an SSRI, feels nauseous for 10 days, has no idea if that’s normal, and stops. By the time I see them at the next appointment, they’ve been off the medication for three weeks and we’re starting over. The clinical question isn’t just which medication to prescribe. It’s who is watching what happens after the prescription is written. Daily check-ins during those first 6 to 8 weeks change the outcome because they catch the nausea, catch the anxiety spike, catch the moment a patient is about to give up on something that might have worked.”

SiggyMD provides clinician-supervised care for depression and anxiety, with daily check-ins that build a longitudinal picture of how medication is actually affecting you during the weeks that matter most. No name, no email, no account required to start. A licensed prescriber reviews every treatment plan.

For more on related topics, see our guides on how to know if your antidepressant is working, what to tell your psychiatrist about medication, and adjusting antidepressant dose without losing continuity.

Start your anonymous intake with SiggyMD.

What Members Are Saying

RC

R.C., 33

Stopped Too Early, Restarted with Better Support

“I stopped my first SSRI after two weeks because I felt worse, not better. I felt anxious and nauseous and I had no idea that was normal. If someone had just told me that the first two weeks would feel like that, I would have kept going. The second time around, I had daily check-ins and I knew what to expect. Six weeks in, I was finally feeling like myself.”

AB

A.B., 41

Late Responder Who Almost Quit at Week 5

“My prescriber told me four to eight weeks. At week 5 I still didn’t feel much different. I was ready to stop. But the daily check-in caught that I was sleeping better and getting out of the house more, even if my mood hadn’t shifted. That data point was enough to keep me going. By week 8, I knew it was working.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Sources

1. National Institute of Mental Health. Depression: What You Need to Know. NIMH. Reviewed 2024.

2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA Publishing, Third Edition.

3. Uher R, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the GENDEP study. Journal of Clinical Psychiatry. 2011;72(11):1478-1484.

4. de Vries YA, et al. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. British Journal of Psychiatry. 2019;214(1):5-12.

5. Kudlow PA, et al. Early Response to Antidepressant Medications in Adults With Major Depressive Disorder: A Naturalistic Study and Odds of Remission at 14 Weeks. Journal of Clinical Psychiatry. 2022.

6. Bener A, et al. The short-term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence. PMC. 2025.

7. Fava M, et al. The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals. 2014;7(2):183-206.

8. Taylor MJ, et al. Onset of action of antidepressants. BMJ. 2006;331:1114-1118.